Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology
Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up... see more

Recent & Breaking News (GREY:COTQF)

Critical Outcome Technologies Receives Orphan Drug Designation For COTI-2

Marketwired June 17, 2014

Critical Outcome Technologies to Commence Trading in U.S. on OTCQB Under Symbol COTQF

Marketwired June 16, 2014

Critical Outcome Technologies Inc.: SeeThruEquity Initiates Research Coverage

Marketwired June 13, 2014

Critical Outcome Technologies Invited to Present at 16th International p53 Workshop in Sweden

Marketwired June 13, 2014

Critical Outcome Technologies Inc. Completes Financing

Marketwired June 4, 2014

Critical Outcome Technologies Inc. Announces Warrant Term Amendment

Marketwired May 27, 2014

Critical Outcome Technologies Selected to Present at Multiple Investor Conferences in New York City

Marketwired May 27, 2014

Financing Increases Runway to the Clinic for COTI-2, Critical Outcome's Lead Cancer Drug Candidate

Marketwired May 1, 2014

Critical Outcome Technologies Announces Warrant Issuance

Marketwired April 14, 2014

Critical Outcome Technologies Announces Warrant Issuance

Marketwired April 14, 2014

Critical Outcome Technologies Applies for Orphan Drug Designation for COTI-2 Treatment of Ovarian Cancer

Marketwired April 4, 2014

Critical Outcome Technologies Applies for Orphan Drug Designation for COTI-2 Treatment of Ovarian Cancer

Marketwired April 4, 2014

Critical Outcome Technologies Reports Third Quarter Results

Marketwired March 14, 2014

Critical Outcome Technologies Inc. Announces Warrant Term Amendment

Marketwired March 7, 2014

Critical Outcome Technologies Identifies Experienced Partner for Clinical Development of COTI-2

Marketwired February 26, 2014

Critical Outcome Technologies Completes Private Placement

Marketwired February 6, 2014

Critical Outcome Technologies Announces Engagement of Maxim Group LLC

Marketwired February 5, 2014

Critical Outcome Technologies Reports Second Quarter Results

Marketwired December 18, 2013

Critical Outcome Technologies Awards Stock Options

Marketwired December 6, 2013

Critical Outcome Technologies Provides Business and Scientific Update at Annual General Meeting

Marketwired December 6, 2013